{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:51:55Z","timestamp":1792277515774,"version":"4.4.0"},"reference-count":34,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,11,30]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>In relapsed\/refractory MM, venetoclax plus bortezomib and dexamethasone appears to be safe and efficacious. This is a novel therapeutic approach for MM.<\/jats:p>","DOI":"10.1182\/blood-2017-06-788323","type":"journal-article","created":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T01:00:32Z","timestamp":1503968432000},"page":"2392-2400","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":240,"title":["Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM"],"prefix":"10.1182","volume":"130","author":[{"given":"Philippe","family":"Moreau","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire de Nantes, University Hospital H\u00f4tel-Dieu, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher","family":"Chanan-Khan","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Jacksonville, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Royal Melbourne Hospital, Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Melbourne, VIC, Australia;"},{"name":"Victorian Comprehensive Cancer Centre, Melbourne, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit B.","family":"Agarwal","sequence":"additional","affiliation":[{"name":"The University of Arizona Cancer Center, Tucson, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Regional Universitaire Lille, H\u00f4pital Claude Huriez, Lille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Nantes, University Hospital H\u00f4tel-Dieu, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Punnoose","sequence":"additional","affiliation":[{"name":"Genentech Inc., South San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn","family":"Cordero","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wijith","family":"Munasinghe","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Jia","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Hamed","family":"Salem","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL;"},{"name":"Department of Clinical Pharmacy, Ain Shams University, Cairo, Egypt;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Freise","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel D.","family":"Leverson","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sari Heitner","family":"Enschede","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy A.","family":"Ross","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo C.","family":"Maciag","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Verdugo","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; and"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"20","key":"2019111905340872100_B1","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","article-title":"Frontline therapy of multiple myeloma","volume":"125","author":"Moreau","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111905340872100_B2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-016-0282-1","article-title":"Novel agents in the treatment of multiple myeloma: a review about the future","volume":"9","author":"Naymagon","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"1-2","key":"2019111905340872100_B3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.imlet.2013.09.015","article-title":"Reprogramming cell death: BCL2 family inhibition in hematological malignancies","volume":"155","author":"Scarf\u00f2","year":"2013","journal-title":"Immunol Lett"},{"issue":"2","key":"2019111905340872100_B4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2019111905340872100_B5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nm.3076","article-title":"Apoptosis therapy: driving cancers down the road to ruin","volume":"19","author":"Green","year":"2013","journal-title":"Nat Med"},{"issue":"14","key":"2019111905340872100_B6","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1182\/blood-2010-11-317438","article-title":"ABT-737 is highly effective against molecular subgroups of multiple myeloma","volume":"118","author":"Bodet","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111905340872100_B7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/leu.2015.184","article-title":"BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics","volume":"30","author":"Touzeau","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"2019111905340872100_B8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","article-title":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","volume":"16","author":"Ashkenazi","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"2019111905340872100_B9","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/cdd.2008.37","article-title":"Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?","volume":"15","author":"Labi","year":"2008","journal-title":"Cell Death Differ"},{"issue":"4","key":"2019111905340872100_B10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111905340872100_B11","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"2019111905340872100_B12","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"issue":"23","key":"2019111905340872100_B13","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.254.254","article-title":"A phase 1 study of venetoclax (ABT-199 \/ GDC-0199) monotherapy in patients with relapsed\/refractory non-Hodgkin lymphoma [abstract].","volume":"126","author":"Gerecitano","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111905340872100_B14","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/leu.2013.216","article-title":"The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma","volume":"28","author":"Touzeau","year":"2014","journal-title":"Leukemia"},{"issue":"22","key":"2019111905340872100_B15","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.488.488","article-title":"Venetoclax monotherapy for relapsed\/refractory multiple myeloma: safety and efficacy results from a phase I study [abstract].","volume":"128","author":"Kumar","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2019111905340872100_B16","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.3324\/haematol.2016.160408","article-title":"Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14)","volume":"102","author":"Touzeau","year":"2017","journal-title":"Haematologica"},{"issue":"14","key":"2019111905340872100_B17","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2016-03-704908","article-title":"Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1","volume":"128","author":"Gong","year":"2016","journal-title":"Blood"},{"issue":"7626","key":"2019111905340872100_B18","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"issue":"5","key":"2019111905340872100_B19","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"2019111905340872100_B20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.leukres.2015.12.005","article-title":"Signaling mechanisms of bortezomib in TRAF3-deficient mouse B lymphoma and human multiple myeloma cells","volume":"41","author":"Edwards","year":"2016","journal-title":"Leuk Res"},{"issue":"14","key":"2019111905340872100_B21","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.1158\/0008-5472.CAN-05-0676","article-title":"Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells","volume":"65","author":"Qin","year":"2005","journal-title":"Cancer Res"},{"issue":"5","key":"2019111905340872100_B22","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/leu.2015.350","article-title":"Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax","volume":"30","author":"Matulis","year":"2016","journal-title":"Leukemia"},{"key":"2019111905340872100_B23","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1186\/s12885-016-2702-6","article-title":"Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data","volume":"16","author":"James","year":"2016","journal-title":"BMC Cancer"},{"issue":"2","key":"2019111905340872100_B24","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/sim.6941","article-title":"A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials","volume":"36","author":"Pan","year":"2017","journal-title":"Stat Med"},{"key":"2019111905340872100_B25","year":"2015"},{"key":"2019111905340872100_B26","unstructured":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v4.03. http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 3 May, 2017."},{"issue":"9","key":"2019111905340872100_B27","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"18","key":"2019111905340872100_B28","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2019111905340872100_B29","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/sim.7236","article-title":"Patient subgroup identification for clinical drug development","volume":"36","author":"Huang","year":"2017","journal-title":"Stat Med"},{"key":"2019111905340872100_B30","article-title":"Moving beyond maximum tolerated dose for targeted oncology drugs: use of clinical utility index to optimize venetoclax dosage in multiple myeloma patients [published online ahead of print 17 April 2017]","author":"Freise","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"2019111905340872100_B31","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/jcph.821","article-title":"Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma","volume":"57","author":"Salem","year":"2017","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"2019111905340872100_B32","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111905340872100_B33","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"issue":"23","key":"2019111905340872100_B34","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","article-title":"Randomized phase 2 study: elotuzumab plus bortezomib\/dexamethasone vs bortezomib\/dexamethasone for relapsed\/refractory MM","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/22\/2392\/1403811\/blood788323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/22\/2392\/1403811\/blood788323.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T10:34:31Z","timestamp":1574159671000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/22\/2392\/36574\/Promising-efficacy-and-acceptable-safety-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,30]]},"references-count":34,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2017,11,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-06-788323","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,30]]}}}